Product nameAnti-KREMEN2 antibody [EPR9170]
DescriptionRabbit monoclonal [EPR9170] to KREMEN2
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to residues in Human KREMEN2 (Q8NCW0).
- Lymph node, fetal heart, and SW480 lysates
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab156007 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 49 kDa.|
FunctionReceptor for Dickkopf protein. Cooperates with Dickkopf to block Wnt/beta-catenin signaling. Forms a ternary complex with Dkk1 and LRP6 and induces rapid endocytosis and removal of the Wnt receptor LRP6 from the plasma membrane.
Sequence similaritiesContains 1 CUB domain.
Contains 1 kringle domain.
Contains 1 WSC domain.
DomainBinding to ERLEC1 is mediated by the oligosaccharides linked to the kringle domain.
- Information by UniProt
- Dickkopf receptor 2 antibody
- KREM2_HUMAN antibody
- KREMEN 2 antibody
All lanes : Anti-KREMEN2 antibody [EPR9170] (ab156007) at 1/1000 dilution
Lane 1 : lymph node lysate
Lane 2 : fetal heart lysate
Lane 3 : SW480 lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 49 kDa
Observed band size: 42 kDa why is the actual band size different from the predicted?
ab156007 has not yet been referenced specifically in any publications.